Podcast Episodes
Back to Search251: Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works
Episode 251
Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one o…
1 month ago
250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 2
Episode 250
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process…
1 month, 1 week ago
249: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 1
Episode 249
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the pa…
1 month, 1 week ago
248: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 2
Episode 248
Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in t…
1 month, 2 weeks ago
247: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 1
Episode 247
When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic p…
1 month, 2 weeks ago
246: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 2
Episode 246
Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a …
1 month, 3 weeks ago
245: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 1
Episode 245
Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?
Tibor Anderlei, Chief Scientific Off…
1 month, 3 weeks ago
244: Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC
Episode 244
When a single mismanaged tech transfer threatens an entire development program, pressure on CMC leaders and bioprocess teams is intense. The truth? T…
2 months ago
243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework
Episode 243
What if the hidden cost of your bioprocess lies not in the technology, but in what you don’t document?
Too often, biotech teams discover too late that…
2 months ago
242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 2
Episode 242
What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?
This conversation features Steve Oh, a lead…
2 months, 1 week ago